Protagenic Therapeutics, Inc.new (PTIX): Nasdaq/NYSE listing notice — Protagenic Therapeutics gets Nasdaq notice for missing annual meeting; sets Feb 21, 2025 meeting

Protagenic Therapeutics, Inc.new

Received Nasdaq notice on Jan 15, 2025 for failing to hold annual meeting within 12 months of FY 2023 end (Listing Rule 5620(a)).
Company has scheduled annual meeting to occur no later than February 21, 2025 to regain compliance.
No immediate effect on listing of PTIX or PTIXW on Nasdaq Capital Market.
Will submit matter to Nasdaq Hearings Panel as part of ongoing listing discussions.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a), 5810(c)(2)(G)

Exact text from the filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a), 5810(c)(2)(G)

Exact text from the filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasdaq noted that the Company has not yet held an annual meeting of shareholders within twelve months of the end of its December 31, 2023 fiscal year, as required under Listing Rules 5620(a) and 5810(c)(2)(G). The Company has already scheduled its annual meeting to occur no later than February 21, 2025, and is committed to addressing this compliance matter. This notification is par

View on SEC.gov

Browse all listing & compliance notices →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001493152-25-002448

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.